Companies › BTAI
BioXcel Therapeutics Inc (BTAI)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001720893 · EDGAR filings · Updated 2026-07-06
BioXcel Therapeutics Inc (BTAI) has reported institutional ownership of 20.1%, with 39 institutional managers holding positions valued at $7.27M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-06 — Current report (8-K) filed
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-05-22 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, BioXcel Therapeutics Inc has 39 institutional holders and institutional ownership of 20.1%.
Insider activity
Insiders reported 46 transactions (0 buys, 0 sells) across 5 reporting insiders, with a net reported value of $0.
Data flags from SEC filings
Related companies
MediciNova Inc (MNOV) · BIOHARVEST SCIENCES INC (BHST) · CINGULATE INC (CING) · Koninklijke Philips NV (PHG) · NEUPHORIA THERAPEUTICS IN (NEUP) · Kyntra Bio Inc (KYNB)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-06.